Whereas, comparative genomics juxtaposes two or more genome sequences at the level of gene content and organization [ 25, 26].
With more and more genome sequences released, identifying new bioactive peptides/proteins by computational genomics approaches is becoming quite valuable.
As more and more genome sequences are being published, the number of identified histidine kinases is rapidly growing.
As more genome sequences are becoming available, we are noticing the emergence of underexplored or neglected organisms as alternative resources for new therapeutic agents.
As more and more genome sequences are completed, it is becoming increasingly evident that our understanding of the function of most bacterial gene products is lacking.
Finally, we compare the genome sequence assembled using our hybrid strategy to a classical reference assembly using the same data as input and show that with the availability of a reference genome, it pays off to use the hybrid de novo strategy, rather than a classical reference assembly, because more genome sequences are preserved using the former.
The use of Saccharomyces cerevisiae as a model organism continues to increase as more genome sequences from higher eukaryotes become available and investigators who have previously concentrated on studying genes in larger eukaryotes now address the function of potential yeast homologs.
At present, as much more genome sequences are available, we can quantify it in more detail.
The widespread occurrence of NISE is becoming increasingly apparent as more genome sequences are reported [1], [3], [62], [63], [64].
This approach may also be the basis to define both the true "core genome" and the ever expanding "pan genome" of pseudomonads when more genome sequences are available.
This problem, which is inherent to all metagenomic studies, will likely be overcome as more genome sequences of less represented phyla become available.
